Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361694 · ClinicalTrials.gov registry record
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
A clinical trial of Multiple Myeloma and Smoldering Multiple Myeloma, sponsored by University of Miami.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05361694 is a study of Multiple Myeloma and Smoldering Multiple Myeloma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 1,000 participants, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05361694, a study of Multiple Myeloma and Smoldering Multiple Myeloma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.
Conditions Studied
Study Locations (1)
Florida
- University of Miami Hospitals - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2027-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05361694
The ClinicalTrials.gov registry entry for NCT05361694 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% higher). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT05361694 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05361694 about?
NCT05361694 is a clinical study titled "Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions". The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.
What is the current status of trial NCT05361694?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2022-04-12. Estimated completion is 2027-07-01.
What conditions does trial NCT05361694 study?
This clinical trial studies the following conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance.
Who is sponsoring clinical trial NCT05361694?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05361694 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.